Powerful new cocktail aims to beat back aggressive rectal cancer
NCT ID NCT07549399
First seen Apr 29, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tests whether adding a targeted therapy (cetuximab or bevacizumab) and an immunotherapy drug (PD-1 antibody) to standard short-course radiation and chemotherapy can better control high-risk rectal cancer that is not caused by certain gene faults. About 204 adults with this specific cancer type will be randomly assigned to the new combo or standard treatment. The goal is to see if the new approach improves how long people stay cancer-free and reduces the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510065, China
Conditions
Explore the condition pages connected to this study.